This is a great find. I have read many posts of people suggesting Leo go for this. Thanks for actually providing some evidence. I think B is derisked and since it is phase 3 ready, I think there is a high likelihood it is selected. B’s success in relative short order will also bring the fund success. I can’t believe other antibiotics are positioned as nicely.
3